Is the ChondroFiller injection right for your thumb?

If steroid injections at the thumb base have stopped giving meaningful relief, and surgery still feels like a step too far, ChondroFiller injection is worth understanding. It occupies the space between those two options — a single outpatient injection that works by laying down a collagen scaffold inside the joint, which then recruits the body's own repair cells rather than simply masking pain.

The treatment is best suited to patients with focal cartilage damage or early-to-moderate arthritis at the trapeziometacarpal (TMC) joint — the knuckle at the base of the thumb where most thumb OA begins. In clinical terms, this broadly spans Eaton-Littler stages I through IV, though outcomes are likely strongest where some cartilage architecture remains rather than in fully bone-on-bone joints. Evidence from hip data reinforces the same principle: patients with advanced, diffuse joint degeneration tend to respond poorly, so honest patient selection matters.

The procedure itself is an ultrasound-guided outpatient injection — no theatre, no anaesthetic beyond a local, no overnight stay. The evidence base specific to the thumb is early-stage and encouraging rather than established: a prospective study of 43 patients reported significant pain reduction and functional gains at six months, but larger controlled trials are still needed.

What happens to the thumb base joint

The trapeziometacarpal joint sits where the base of the thumb meets the wrist — a saddle-shaped articulation engineered for the wide arc of motion that grip, pinch, and rotation demand. That geometry also concentrates load: even routine tasks such as opening a jar or turning a key generate forces many times body weight across a joint surface roughly the size of a thumbnail.

Cartilage at the TMC wears unevenly, thinning first on the palmar surface where pinch stress is highest. Early loss produces aching pain at the base of the thumb during gripping and twisting tasks, alongside a gradual fall in pinch strength. As degeneration progresses, the joint's mechanics shift more broadly: three-dimensional motion studies show that the metacarpophalangeal and interphalangeal joints develop compensatory hypermobility as the TMC stiffens — a downstream pattern that compounds loading across the whole thumb ray rather than isolating it to one joint.

Clinicians grade this progression using the Eaton-Littler classification, from stage I (early cartilage softening with preserved joint space) through to stage IV (advanced joint-space loss with possible subluxation and pantrapezial involvement). The staging system matters practically: it anchors conversations about what intervention is appropriate and why, and it reflects how much cartilage architecture — the biological resource that any regenerative approach depends on — is still present.

How the ChondroFiller injection works at the thumb base

ChondroFiller is classified as a CE-marked Class III medical device — a type I collagen hydrogel — rather than a drug or biologic in the conventional sense. That distinction shapes how it is regulated and how it behaves once it is inside the joint.

Delivered as an ultrasound-guided outpatient injection, the gel fills the cartilage defect and self-sets in approximately three to five minutes. The rapid solidification is practically important: the material stays where it is placed rather than dispersing into the joint fluid. This forms a porous collagen scaffold — a three-dimensional architecture that the body can inhabit.

What happens next is the basis for calling the process acellular matrix-induced chondrogenesis. No cells are loaded into the gel before injection; instead, the scaffold draws the patient's own progenitor cells in from the surrounding tissue. A 2025 ex vivo osteochondral model measured a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14, confirming that cellular infiltration occurs rapidly and is not merely theoretical.

The scaffold chemistry is the same regardless of which joint is being treated. What changes is the dose. At the thumb base, the recommended fill volume is 0.6–0.8 mL, applied flush with the cartilage surface. Wrist arthroscopy data from Demmer et al. (2025) showed that fibrous tissue formation occurred exclusively in overfilled defects — flush applications were free of it. Precise volume control in the constrained anatomy of a small hand joint is therefore a technical requirement, not a minor procedural detail.

What the clinical evidence shows for the thumb base

The most relevant clinical dataset comes from Corain et al., published in 2025 (PMC12213533), which prospectively followed 43 patients with trapeziometacarpal osteoarthritis who received a single intra-articular ChondroFiller injection under fluoroscopic guidance. The cohort spanned both early-stage disease (Eaton-Littler I–II) and more advanced joint involvement (III–IV). Both groups achieved highly significant reductions on the Numeric Rating Scale for pain and meaningful improvements on the DASH questionnaire — a standardised measure of arm, shoulder, and hand disability — at 30 days and again at six months.

The study did not stop at symptom scores. Post-treatment MRI scans showed less swelling in the bone beneath the joint surface (reduced bone marrow oedema), a reduction in fluid collecting around the joint (diminished periarticular effusion), and visible widening of the joint space. These structural signals matter because they suggest something is changing in the joint environment, not merely in how patients rate their pain.

Functional gains reinforced this picture. Both grip strength, measured on a Jamar dynamometer, and pinch strength improved significantly — the kind of objective finding that correlates with the daily tasks, such as gripping and pinching, that thumb base arthritis makes hardest.

Published data currently extends to six months for the TMC joint. For broader context, the knee evidence base runs to 12–36 months with approximately 30-point IKDC score gains across cohorts, and a hip series of 26 patients reported 17 of 21 evaluable cases achieving good or excellent results at three to five years. The thumb base dataset is earlier in its development, as the research summary notes — but the six-month trajectory across both early and advanced cohorts is consistent and statistically robust. Separately, Demmer et al. (2025) confirmed superior cartilage quality scores at follow-up arthroscopy in ChondroFiller-treated wrist patients versus controls, lending additional cross-joint credibility to the scaffold's performance in small hand joints.

How ChondroFiller compares to other thumb treatments

Placing ChondroFiller injection alongside the other treatments available for thumb base OA makes the choice clearer — provided each option is assessed for what it does and does not do.

Corticosteroids and hyaluronic acid are palliative. A 2024 meta-analysis of ten randomised controlled trials found no meaningful difference between the two for pain, grip strength, or function in thumb OA — neither changes the structural state of the joint. Corticosteroids do have a legitimate short-term role: during an acute flare, a steroid injection can settle inflammation quickly and is sometimes used before further assessment. But relief typically lasts around four to five months, diminishes with repeat use, and leaves the underlying cartilage unchanged.

PRP has been proposed as a regenerative alternative at this joint, but a 2025 double-blind trial of 90 patients found it performed no better than saline at the thumb base. It does not currently carry a supported regenerative role here.

ChondroFiller injection is the only option in this landscape that targets the structural deficit rather than managing symptoms around it. The scaffold provides a physical matrix for the patient's own progenitor cells to populate — addressing the cartilage problem directly rather than masking it.

Trapeziectomy — surgical removal of the trapezium — remains the UK gold standard once disease reaches end stage. It is irreversible, requires operating-theatre conditions, and involves a substantial rehabilitation period. ChondroFiller sits in the intermediate space between injections that have stopped working and surgery that cannot be undone: a realistic pathway for patients who are not yet surgical candidates, or who wish to keep that option available for as long as possible.

The injection appointment, recovery, and next steps

On the day of treatment, the appointment is short, outpatient, and takes place outside an operating theatre. ChondroFiller injection at the thumb base is delivered under image guidance — ultrasound or fluoroscopy — allowing the clinician to position the needle accurately within the TMC joint's confined anatomy and confirm placement before the gel is introduced. Precision at this stage matters: in a small joint, where the available space is limited, accurate delivery directly affects how the scaffold sits and integrates.

After the injection, a brace or splint is fitted, and this has a mechanical rationale rather than being merely precautionary. A 2024 biomechanical in-vitro study confirmed that ChondroFiller is initially unstable under full cyclic loading — the scaffold has not yet integrated, and early unprotected movement is the risk variable, not the collagen gel itself. Protecting the joint during this window gives the matrix time to stabilise and provides the conditions for the host's own progenitor cells to begin migrating into the scaffold — the process the regenerative response depends on.

The protected phase is followed by a graduated return to hand function, supported by therapy where appropriate. Most patients manage rehabilitation on an outpatient basis with no hospitalisation required.

Suitability is established at a specialist assessment, which should include imaging to confirm joint staging. The patients most likely to benefit tend to have focal, contained cartilage damage rather than joint-wide end-stage degeneration — a distinction that examination and imaging can clarify before any decision is made.

Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street. An initial assessment there establishes joint staging and whether ChondroFiller injection is appropriate for an individual presentation.

1. [1] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: 12–60-month cohort. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing for focal knee cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration (2025). (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures (Demmer et al. 2025). (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y